-
Certolizumab pegol, sold
under the
brand name Cimzia, is a
biopharmaceutical medication for the
treatment of Crohn's disease,
rheumatoid arthritis, psoriatic...
- system. The use of anti-TNF
monoclonal antibodies such as
adalimumab and
certolizumab have been
approved for
Crohn disease. Andreozzi, Laura; Giannetti, Arianna;...
-
cause confusion in
prescribing and
dispensing and
should be avoided.
Certolizumab pegol, etanercept,
golimumab and
infliximab are alternatives, including...
- in 1998.
Infliximab as well as
other TNF
inhibitors like adalimumab,
certolizumab, and
golimumab are
currently the most
common biologics used in the treatment...
-
monoclonal antibodies (MAbs) (infliximab, adalimumab, golimumab, and
certolizumab pegol) and one
recombinant TNF-α
decoy receptor, etanercept, have been...
- it is in development. For example, CDP870 was UCB's
company code for
certolizumab pegol; UCB
later chose "Cimzia" as its
trade name. Many of
these codes...
-
including Keppra (levetiracetam),
Xyzal (levocetirizine), and
Cimzia (
certolizumab pegol),
which arrived through the
acquisition of Celltech. At the end...
-
inflammatory bowel disease. TNF-α
Inhibitor treatments (infliximab, adalimumab,
certolizumab, natalizumab, and etanercept) are
thought to be the
cause of this rare...
-
achieved with a
monoclonal antibody such as infliximab, adalimumab,
certolizumab pegol, and golimumab, or with a
circulating receptor fusion protein such...
-
arthritis are TNF-α inhibitors,
including infliximab, etanercept, golimumab,
certolizumab pegol and adalimumab, as well as the IL-12/IL-23
inhibitor ustekinumab...
